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Increasing microtubule acetylation rescues axonal
transport and locomotor deﬁcits caused by LRRK2
Roc-COR domain mutations
Vinay K. Godena1,2,3,*, Nicholas Brookes-Hocking4,*, Annekathrin Moller5, Gary Shaw5, Matthew Oswald1,2,w,
Rosa M. Sancho4,w, Christopher C.J. Miller4, Alexander J. Whitworth1,2,3 & Kurt J. De Vos3,5
Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of
Parkinson’s disease. LRRK2 is a multifunctional protein affecting many cellular processes and
has been described to bind microtubules. Defective microtubule-based axonal transport
is hypothesized to contribute to Parkinson’s disease, but whether LRRK2 mutations affect
this process to mediate pathogenesis is not known. Here we ﬁnd that LRRK2 containing
pathogenic Roc-COR domain mutations (R1441C, Y1699C) preferentially associates with
deacetylated microtubules, and inhibits axonal transport in primary neurons and in Drosophila,
causing locomotor deﬁcits in vivo. In vitro, increasing microtubule acetylation using
deacetylase inhibitors or the tubulin acetylase aTAT1 prevents association of mutant LRRK2
with microtubules, and the deacetylase inhibitor trichostatin A (TSA) restores axonal
transport. In vivo knockdown of the deacetylases HDAC6 and Sirt2, or administration of TSA
rescues both axonal transport and locomotor behavior. Thus, this study reveals a pathogenic
mechanism and a potential intervention for Parkinson’s disease.
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D
ominant mutations in leucine-rich repeat kinase 2
(LRRK2) are the most common genetic cause of
Parkinson’s disease (PD), and genome-wide association
studies have highlighted the LRRK2 locus as a risk factor for
sporadic PD1–5. LRRK2 is a multifunctional, multi-domain
protein and dominant mutations have been identiﬁed in the
Ras of complex (Roc) GTPase protein domain (R1441C, R1441G,
R1441H), the carboxy-terminal of Roc (COR) domain (Y1699C)
and the kinase domain (G2019S and I2020T). Mutations in the
Roc and COR domains decrease GTPase activity6,7, whereas the
G2019S mutation increases kinase activity6,8,9. How LRRK2
mutations confer toxicity is not yet clear, but may involve the
possible physiological function of LRRK2 in the maintenance of
axonal integrity. Indeed, there is evidence that the overexpression
of LRRK2 causes neurite shortening, whereas the loss of LRRK2
function in mouse neurons results in elongation of neuronal
processes and increased branching10–13. The molecular details
underlying mutant LRRK2’s effects on neurites are not fully
understood, but may involve interactions with microtubules14–18.
The architecture of neurons makes them particularly dependent
on efﬁcient intracellular transport of cargoes such as organelles
and proteins to maintain structural integrity and function. Since
defective axonal transport, which utilizes microtubules as
transport tracks, has been proposed as a mechanism for PD19–
24, we hypothesized that mutant LRRK2 may disturb
microtubule-based axonal transport.
Here we show that LRRK2 Roc-COR mutants disrupt axonal
transport in vitro and in vivo to induce locomotor deﬁcits by
binding to deacetylated microtubules. Increasing microtubule
acetylation prevents microtubule association, restores axonal
transport and rescues locomotor deﬁcits caused by LRRK2
Roc-COR mutants. Thus, our data reveals a pathogenic
mechanism and a potential therapeutic intervention for PD.
Results
Roc-COR mutations inhibit axonal transport and locomotion.
To study the effect of pathogenic LRRK2 mutations on axonal
transport, we expressed wild-type (WT) or mutant (R1441C,
Y1699C or G2019S) LRRK2 variants in rat cortical neuron
cultures, and analysed the movement of mitochondria from
time-lapse recordings. Whereas the expression of LRRK2-WT or
LRRK2-G2019S did not affect mitochondrial transport, both
LRRK2-R1441C and LRRK2-Y1699C signiﬁcantly inhibited the
transport of mitochondria by disrupting both anterograde and
retrograde motility (Fig. 1a). Detailed analysis revealed that both
LRRK2-R1441C and LRRK2-Y1699C decreased anterograde and
retrograde transport frequencies, with a concomitant increase in
the duration of pauses and decreased velocities (Supplementary
Fig. 1).
To investigate if this axonal transport defect occurred in vivo,
we analysed the transport of mitochondria in motor neurons of
Drosophila larvae expressing human LRRK2 variants. Similar
to mammalian neurons, the expression of LRRK2-WT or
LRRK2-G2019S did not adversely affect mitochondrial transport,
whereas the LRRK2-R1441C or LRRK2-Y1699C mutants reduced
the number of motile mitochondria in both anterograde and
retrograde directions (Fig. 1b). Moreover, the effects are
evolutionarily conserved as the expression of Drosophila
Lrrk-R1069C (equivalent to LRRK2-R1441C) or Lrrk-Y1383C
(equivalent to LRRK2-Y1699C) inhibited both anterograde and
retrograde transport, while the expression of Lrrk-WT similarly
had no effect on transport (Supplementary Fig. 2). Together these
results demonstrate that the expression of pathogenic Roc-COR
variants of LRRK2 or its Drosophila homologue Lrrk inhibit
bidirectional axonal transport of mitochondria in vitro and
in vivo.
The Drosophila model enabled us to investigate whether the
aberrant axonal transport resulted in a functional deﬁcit of the
motor system. Adult ﬂies expressing variant forms of LRRK2 or
Lrrk in motor neurons were assayed for climbing and ﬂight
ability. Flies expressing WT LRRK2/Lrrk or LRRK2-G2019S
showed no defect in locomotion compared with controls,
consistent with a lack of effect on axonal transport (Fig. 1c and
Supplementary Fig. 2). However, LRRK2-R1441C and LRRK2-
Y1699C caused a signiﬁcant decrease in both climbing and ﬂight
ability (Fig. 1c). Consistent with a conserved effect of these
mutations, Lrrk-R1069C and Lrrk-Y1383C also caused locomotor
deﬁcits (Supplementary Fig. 2).
Roc-COR mutants form ﬁlamentous structures on micro-
tubules. The bidirectional nature of the axonal transport defect
suggested the disturbance of a common transport component
such as microtubules. It has been reported that LRRK2 can
interact with microtubules and even alter tubulin acetylation14–18.
Importantly, the acetylation status of microtubules is known to
inﬂuence the rate of transport along them, with increased
acetylation promoting axonal transport25,26. Therefore, we
hypothesized that LRRK2 Roc-COR mutants may affect the
equilibrium of microtubules. To address this, we analysed the
association of LRRK2 variants with microtubules in mammalian
CV1 and HEK293 cells, focusing speciﬁcally on acetylated
microtubules. In contrast to LRRK2-WT, we found that
LRRK2-R1441C and LRRK2-Y1699C had a propensity to form
ﬁlamentous structures that appeared to align with microtubules
(Fig. 2). These structures are reminiscent of previously
reported skein-like LRRK2 structures17,27. Furthermore, where
LRRK2-R1441C or LRRK2-Y1699C was present, a-tubulin
acetylation was lacking. These observations are consistent with
LRRK2-R1441C and LRRK2-Y1699C inhibiting axonal transport
by interfering with microtubule acetylation.
Increasing microtubule acetylation inhibits LRRK2 ﬁlaments.
We next investigated whether the interaction of LRRK2 variants
with deacetylated microtubules was reversible and sensitive
to microtubule acetylation. We treated CV1 and HEK293 cells
with the broad deacetylase inhibitor trichostatin A (TSA),
which promotes a-tubulin acetylation26, and analysed ﬁlament
formation. In both CV1 and HEK293 cells, TSA treatment
signiﬁcantly reduced the formation of ﬁlamentous LRRK2 (Fig. 2)
The family of histone deacetylases (HDACs) is classiﬁed into
four groups based on function and DNA sequence similarity.
Classes I, IIa and IIb are considered the classical HDACs whose
activities are inhibited by TSA. Class III comprises a family of
NADþ -dependent proteins called the Sirtuins (SIRTs) that are
not affected by TSA. Class IV is an atypical class based solely on
DNA sequence similarity to the others. Both the class IIb member
HDAC6 and class III member SIRT2 have been shown to
deacetylate a-tubulin28,29 and conversely their inhibition
increases microtubule acetylation. Thus, although in our
assays HDAC6 was likely to be the main target of TSA, other
pathways could have been affected by TSA treatment. To more
selectively target microtubule acetylation, we treated HEK293
cells expressing LRRK2 Roc-COR mutants with the speciﬁc
HDAC6 inhibitor tubastatin-A30–32 or the SIRT2-speciﬁc
inhibitor AGK2 (ref. 33). Speciﬁc inhibition of either HDAC6
or SIRT2 prevented the formation of ﬁlamentous LRRK2 to the
same extend as TSA (Fig. 3).
To further characterize the potential role of microtubule
acetylation in the LRRK2 Roc-COR mutant ﬁlamentous
phenotype, we expressed the a-tubulin acetyl transferase aTAT1
(also called MEC17)34,35. Because a-tubulin is the major cellular
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substrate of aTAT1, the overexpression of aTAT1 speciﬁcally
increases microtubule acetylation36. aTAT1 expression also
signiﬁcantly reversed the ﬁlamentous LRRK2 Roc-COR mutant
phenotype (Fig. 4) conﬁrming that microtubule acetylation
regulates the association of LRRK2 Roc-COR mutants with
microtubules.
Together these ﬁndings support previous reports that LRRK2
associates with microtubules and indicate that LRRK2 Roc-COR
mutants interfere with a-tubulin acetylation, which can be
restored by the inhibition of the deacetylase enzymes HDAC6
and SIRT2 or by the overexpression of aTAT1.
TSA restores axonal transport and locomotion. Reversal of the
association of LRRK2 Roc-COR mutants with deacetylated
microtubules prompted us to address whether modulating
microtubule acetylation could also reverse the axonal transport
defects in vitro and in vivo. We ﬁrst targeted the tubulin
deacetylases in vivo using transgenic Drosophila HDAC6 or Sirt2
RNA interference (RNAi) lines. Loss of either HDAC6 or Sirt2
effectively restored axonal transport of mitochondria in LRRK2
Roc-COR mutant transgenic ﬂies (Fig. 5a,b). Moreover, the
knockdown of HDAC6 or Sirt2 was able to signiﬁcantly rescue
climbing and ﬂight deﬁcits caused by mutant LRRK2 (Fig. 5c).
The ability of TSA to prevent mutant LRRK2 from aberrant
binding to microtubules makes this an attractive therapeutic
intervention. We tested this idea by treating primary rat neurons
expressing LRRK2-Y1699C with TSA. Encouragingly, this was
able to restore axonal transport to control levels (Fig. 6a). To
extend this observation in vivo, Drosophila expressing the LRRK2
variants were raised on TSA-dosed food. Remarkably, this
completely rescued the transport defects caused by LRRK2-
R1441C or Y1699C (Fig. 6b). Similarly, transport defects caused
by Lrrk-R1069C or Y1383C expression were also restored by
feeding TSA (Supplementary Fig. 3). Thus, both genetic and
pharmacological approaches in vitro and in vivo show that
increasing microtubule acetylation can rescue LRRK2 Roc-COR
mutant-induced axonal transport defects.
Finally, we asked whether treatment with TSA would be able to
rescue the locomotor deﬁcits cause by the defective axonal
transport even after the onset of the phenotype. We took newly
emerged ﬂies expressing WT and mutant forms of LRRK2 or Lrrk
that had been raised on normal food, which as we previously
showed already exhibited climbing and ﬂight deﬁcits (Fig. 1c).
These young adult ﬂies were then fed TSA for 5 days and tested
for locomotion. Notably, even with this modest increase in age,
the locomotor deﬁcit had worsened in control-fed animals
(Fig. 6c and Supplementary Fig. 3c). However, the administration
of TSA was sufﬁcient to fully restore locomotor ability in the
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Figure 1 | LRRK2 Roc-COR domain mutations interfere with axonal
transport. Kymographs show transport of (a) DsRed-labelled mitochondria
in rat cortical neurons transfected to express the indicated acGFP1-tagged
LRRK2 variants (Control is expressing acGFP1 alone) or (b) mito-GFP-
labelled mitochondria in transgenic Drosophila motor neurons expressing
the indicated LRRK2 variants. Charts are mean±s.e.m. of quantiﬁed
mitochondrial transport shown as percentage of total mitochondria.
(c) Locomotion assays for climbing and ﬂight behaviour of LRRK2 variants
expressed in motor neurons by D42-GAL4. Drosophila control is driver/
reporter crossed to a lacZ transgene. *Po0.05, **Po0.01, ***Po0.001,
****Po0.0001, one-way analysis of variance followed by Fisher’s least
signiﬁcant difference post hoc test. (a) N (cells; from four to eight
experiments)¼Ctrl, 5; WT, 12; R1441C, 6; Y1699C, 20; G2019S, 7.
(b) N (animals)¼Ctrl, 10; WT, 10; R1441C, 12; Y1699C, 14; G2019S, 11.
(c) N (animals)¼Ctrl, 95; WT, 141; R1441C, 93; Y1699C, 122; G2019S, 59.
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LRRK2-R1441C- or Y1699C- and Lrkk-R1069C- or Y1383C-
expressing animals (Fig. 6c and Supplementary Fig. 3c).
These results demonstrate that increasing microtubule
acetylation either genetically by knockdown of deacetylase
enzymes or by systemic administration of a deacetylase inhibitor
is sufﬁcient to restore a primary cellular defect and reverse
the associated behavioural disruption, even after the onset of
behavioural symptoms.
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Figure 2 | LRRK2 Roc-COR domain mutants form TSA-sensitive ﬁlamentous structures. CV1 (a) or HEK293 (c) cells were transfected with acGFP1-
tagged LRRK2 variants (green) as indicated. Twenty-four hours after transfection, the cells were treated with vehicle (Ctrl) or 0.5mM TSA for 4 h. After
treatment, the cells were ﬁxed and processed for immunostaining using anti-acetylated a-tubulin antibody (red). Scale bar, 20mm (a), 10mm (c); zoom,
5 mm. The percentage of vehicle (Ctrl) and TSA-treated (TSA) CV1 (b) and HEK293 (d) cells exhibiting ﬁlamentous LRRK2 was quantiﬁed (mean±s.e.m.,
zero values are indicated (0)). **Po0.01, ***Po0.001, ****Po0.0001, two-way analysis of variance followed by Fisher’s least signiﬁcant difference post hoc
test. (b) N (coverslips counted, B50 cells per coverslip; from four experiments)¼WT, 7; WTþTSA, 5; Y1699C, 4; Y1699CþTSA, 5; R1441C, 11;
R1441CþTSA, 4. (d) N (coverslips counted, B50 cells per coverslip; from four experiments)¼WT, 5; WTþTSA, 5; Y1699C, 13; Y1699CþTSA, 5;
R1441C, 15; R1441CþTSA, 5.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6245
4 NATURE COMMUNICATIONS | 5:5245 | DOI: 10.1038/ncomms6245 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
Discussion
Disruption of axonal transport is an early feature in a number of
neurodegenerative diseases including PD19. Analysis of axonal
transport of WT and pathogenic mutants of a-synuclein have
revealed reduced transport rates of the mutants, which may
contribute to the formation of Lewy bodies21. PINK1 and
Parkin, mutations in which cause the majority of early-onset
recessive familial PD37,38, have been shown to directly
affect mitochondrial transport23,24 and this in turn regulates
mitophagy39. Halting of axonal transport has also been
observed in mitochondrial neurotoxin models of sporadic
PD40–42.
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Figure 3 | Both HDAC6 and SIRT2 inhibitors prevent LRRK2 Roc-COR mutant ﬁlamentous structures. (a) HEK293 cells were transfected with
acGFP1-tagged LRRK2 variants (green) as indicated. Twenty-four hours after transfection, the cells were treated with vehicle (Ctrl), 2 mM tubastatin-A
(TubA) or 5 mM AGK2 for 4 h. After treatment, the cells were ﬁxed and processed for immunostaining using anti-acetylated a-tubulin antibody (red).
Scale bar, 10mm; zoom, 5 mm. (b) The percentage of vehicle (Ctrl), TubA and AGK2-treated HEK293 cells exhibiting ﬁlamentous LRRK2 was quantiﬁed
(mean±s.e.m., zero values are indicated (0)). **Po0.01, ****Po0.0001, two-way analysis of variance followed by Fisher’s least signiﬁcant difference
post hoc test. N (coverslips counted,B50 cells per coverslip, from four experiments)¼WT, 5; WTþTubA, 5; WTþAGK2, 5; Y1699C, 13; Y1699CþTubA,
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In this study, we investigated whether PD-associated mutations
in LRRK2 affect axonal transport and cause dysfunction of the
motor system. We found that pathogenic mutations in the
Roc-COR domain of LRRK2 (R1441C and Y1699C) disrupt
axonal transport of mitochondria in vitro in cultured neurons and
in vivo, and cause locomotor deﬁcits in Drosophila. The effects
are evolutionarily conserved since the expression of mutant
Drosophila Lrrk variants also inhibited transport and motor
ability.
LRRK2 has been shown to interact with microtubules but
the physiological relevance of this interaction is poorly
understood14–18. We found that both LRRK2-R1441C and
Y1699C mutants, but not LRRK2-WT, formed ﬁlament-like
structures that decorated deacetylated microtubules. Previous
work has shown that acetylation of microtubules regulates axonal
transport25,26 and has implicated LRRK2 in the regulation of
microtubule acetylation18. We therefore increased microtubule
acetylation using pharmacological inhibitors or RNAi knockdown
of the deacetylase enzymes HDAC6 and SIRT2, or by the
expression of aTAT1 and found that this prevented the
decoration of microtubules by LRRK2-R1441C and Y1699C.
Importantly, increasing microtubule acetylation restored axonal
transport to WT levels in vitro and in vivo.
Interestingly the kinase domain mutant LRRK2-G2019S did
not affect axonal transport. Several groups have shown that the
R1441C and Y1699C mutations inhibit the GTPase activity of
LRRK2 but have normal kinase activity6,7,43,44, whereas LRRK2-
G2019S has increased kinase activity but normal GTPase activity
compared with WT LRRK2 (refs 8,9,45,46). Thus, our results
suggest that the inhibition of axonal transport is likely linked to
decreased LRRK2 GTPase activity. This is in line with increasing
evidence suggesting that the GTPase activity of LRRK2 plays
an important role in pathogenesis47. Interestingly, the
pharmacological inhibition of LRRK2 kinase activity has been
shown to induce a redistribution of LRRK2 that appears similar
to the microtubule-attached distribution we observed with
LRRK2 Roc-COR mutants48 and the binding of LRRK2 to
tubulin was signiﬁcantly enhanced by LRRK2 kinase inhibition in
an indirect reporter assay16. However, since the LRRK2 Roc-COR
mutants analysed here have normal kinase activity6,7,43,44, our
data suggest that the GTPase activity of LRRK2 plays a key role in
LRRK2’s interaction with microtubules. The effect of LRRK2
kinase inhibitors may be explained by a model in which LRRK2
kinase regulates the GTPase via phosphorylation47.
The Drosophila model allowed us to extend our observations of
defective axonal transport in a number of ways. First, it allowed
us to address whether the inhibition of axonal transport by
LRRK2 Roc-COR mutants had any physiological consequences in
adult motor behaviours. We found that Drosophila expressing
LRRK2 Roc-COR mutants also resulted in a deﬁcit of the motor
system, causing a decrease in both climbing and ﬂight ability.
Furthermore, when we restored axonal transport by increasing
microtubule acetylation using HDAC6 or Sirt2 RNAi, this also
restored normal locomotor ability. Thus, these results argue that
inhibition of axonal transport can cause functional deﬁcits
in vivo.
Second, this system also enabled us to assess whether
pharmacological restoration of acetylated microtubules could
reverse the locomotor phenotype after the onset of locomotor
symptoms. Indeed, we found that the systemic administration of
TSA was able to fully restore locomotor ability, showing that the
effects of the LRRK2 Roc-COR mutants are reversible and, at least
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Figure 5 | HDAC6 and Sirt2 RNAi restores axonal transport and locomotion. (a) Kymographs of mitochondria in transgenic Drosophila motor neurons
expressing mito-GFP with indicated LRRK2 variants alone (top) or in combination with HDAC6 or Sirt2 RNAi transgenes. Ctrl RNAi is expressing a lacZ-RNAi
transgene. (b) Charts are mean±s.e.m. of quantiﬁed mitochondrial transport shown as percentage of total mitochondria. (c) Locomotion assays for
climbing behavior of indicated genotypes. Transgene expression is driven by D42-GAL4. Ctrl is driver crossed to a lacZ transgene. *Po0.05, **Po0.01,
***Po0.001, ****Po0.0001, one-way analysis of variance followed by Fisher’s least signiﬁcant difference post hoc test. (b) left chart: N (animals)¼Ctrl
RNAi, 11; R1441C, 9; R1441CþCtrl RNAi, 23; R1441CþHDAC6 RNAi, 13; R1441Cþ Sirt2 RNAi, 12; right chart: N (animals)¼Ctrl RNAi, 11; Y1699C, 11;
Y1699CþCtrl RNAi, 13; Y1699CþHDAC6 RNAi, 15; Y1699Cþ Sirt2 RNAi, 18. (c) left chart: N (animals)¼Ctrl, 379; Ctrl RNAi, 326; R1441C, 367;
R1441CþCtrl RNAi, 245; R1441CþHDAC6 RNAi, 300; R1441Cþ Sirt2 RNAi, 218; right chart: N (animals)¼Ctrl, 329; Ctrl RNAi, 281; Y1699C, 381;
Y1699CþCtrl RNAi, 338; Y1699CþHDAC6 RNAi, 413; Y1699Cþ Sirt2 RNAi, 170.
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in the ﬂy, are amenable to post hoc treatment. Thus, our study
adds PD to the growing list of neurodegenerative diseases that
involve disturbed axonal transport in which deacetylase inhibitors
have been shown to confer protection including Charcot–Marie–
Tooth disease, Alzheimer’s disease, amyotrophic lateral sclerosis
and Huntington’s disease26,49–55.
In conclusion, our results reveal that mutant LRRK2-associated
PD involves defective axonal transport and suggest that treating
with deacetylase inhibitors to restore transport may have
therapeutic potential.
Methods
Plasmids. pAcGFP1-LRRK2-WT, Y1699C and R1441C variants were a gift from
M. Cookson (NIH, Bethesda). pAcGFP1-LRRK2-G2019S was generated by
mutagenesis of pAcGFP1-LRRK2-WT using a QuikChange Site-Directed
Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions.
Mutagenic primers were: 50-caaagattgctgactacagcattgctcagtactgctg-30 (forward) and
50-cagcagtactgagcaatgctgtagtcagcaatctttg-30 (reverse). Mutagenesis was veriﬁed
by sequencing. The pSPORT6-MEC17 (aTAT1) expression plasmid has been
described35 and was a gift from J. Gaertig (University of Georgia, Athens, GA).
Cell culture and plasmid transfection. CV1 and HEK293 cells obtained from the
ATCC were maintained in Dulbecco’s modiﬁed Eagle’s medium (Invitrogen)
containing 4.5 g l 1 glucose, 10% foetal bovine serum (Sera Laboratories), 2mM
L-glutamine (Invitrogen) and 1mM sodium pyruvate (Sigma) and were transfected
using Exgen500 (Fermentas) or Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. All cells were used in experiments 16–24 h post
transfection.
Cortical neurons were isolated and transfected as previously described56–59.
Brieﬂy, cortical neurons were isolated from embryonic day 18 rat embryos and
cultured on glass coverslips coated with poly-L-lysine in six or 12-well plates in
neurobasal medium containing B27 supplement (Invitrogen), 100 IUml 1
penicillin, 100 mgml 1 streptomycin and 2mM L-glutamine. Cells were cultured
for 7 days and then transfected using a calcium phosphate Profection kit
(Promega). For studies on the effects of LRRK2 on axonal transport, neurons were
transfected with twice the amount of LRRK2 plasmid compared with DsRed-Mito
to ensure that all cells visualized for mitochondrial transport expressed LRRK2 and
this was conﬁrmed by AcGFP1 ﬂuorescence.
Antibodies. Anti-acetylated a-tubulin mouse monoclonal antibody was from
Sigma (clone 6-11B-1) and used diluted 1:5,000. Secondary antibodies were Alexa
ﬂuorophore(546 and 633)-coupled goat anti-mouse IgG from Invitrogen (dilution
1:500).
Immunoﬂuorescence analysis of LRRK2 microtubule interaction.
Immunostaining was performed as described previously60. Brieﬂy, CV1 or HEK293
cells on glass coverslips were ﬁxed with 3.7% formaldehyde in PBS for 20min at
room temperature. After washing with PBS, residual formaldehyde was quenched
by incubation with 50mM NH4Cl in PBS for 15min at room temperature, followed
by a second round of washing with PBS. Subsequently, the cells were permeabilized
with  20 C MeOH for 20min or by incubation with 0.2% Triton-X-100 in PBS
for 3min. MeOH or Triton-X-100 was removed by washing with PBS.
After ﬁxing, the cells were incubated with PBS containing 0.2% ﬁsh gelatine
(PBS/F) for 30min at room temperature and then with the primary antibody in
PBS/F for 1 h. After washing with PBS/F, the cells were incubated with secondary
antibody in PBS/F for 45min at room temperature. After a ﬁnal wash, the samples
were mounted in Moviol (Calbiochem) containing 1% DABCO or Dako
ﬂuorescence mounting medium.
Confocal images were recorded with an LSM510Meta (Carl Zeiss) or a Leica
SP5 (Leica Microsystems) confocal microscope using a  63, 1.4NA objective.
Axonal transport of mitochondria in rat cortical neurons. Live microscopy
of mitochondrial axonal transport in cortical neurons was performed with an
Axiovert S100 microscope (Carl Zeiss) equipped with a Lambda LS Xenon-Arc
light source (Sutter Instrument Company, Novato, CA), an EGFP/DsRed ﬁlterset
(Chroma Technology Corp.),  40 EC Plan-Neoﬂuar 1.3 N.A. objective (Zeiss),
Lambda 10-3 ﬁlter wheel (Sutter Instrument Co.) and a Photometrics Cascade-II
512B High Speed EMCCD camera (Photometrics). Post transfection (36–48 h),
neurons on coverslips were transferred to a custom observation chamber mounted
on the stage of the microscope. The cells were maintained at 37 C using an
objective heater (Tempcontrol 37-2, Carl Zeiss) and ‘The Box’ Microscope
Temperature Control System (Life Imaging Systems). Mitochondrial movements
were recorded for 10min with 3 s time-lapse interval using Metamorph software
(Molecular Devices).
Image analysis was performed with ImageJ developed by Wayne Rasband
(NIH, Bethesda, USA; http://rsb.info.nih.gov/ij/) extended with custom plug-ins, or
Metamorph. Calculations of mitochondrial transport parameters were as described
before57,59 except that the overall transport of mitochondria in Figs 1 and 5 were
analysed from kymographs using the SlopeToVelocity plugin described
previously59. Brieﬂy, this plugin calculates the velocity by measuring the distance
between the position of individual mitochondria at the start and end of time-lapse
recordings and dividing by the time elapsed. This yields an overall velocity of
transport that includes anterograde and retrograde movements and stationary
periods. Mitochondria were subsequently classiﬁed as motile (velocity
40.1 mms 1) or stationary (velocity r0.1 mms 1).
Drosophila stocks and procedures. Drosophila were raised under standard
conditions at 25 C on agar, cornmeal and yeast food. Transgenic lines used were:
UAS-LRRK2 WT61, UAS-LRRK2 R1441C62, UAS-LRRK2 Y1699C63, UAS-LRRK2
G2019S61, UAS-Lrrk WT64, UAS-Lrrk R1069C64 and UAS-Lrrk Y1383C63.
D42-GAL4, CCAP-GAL4, UAS-mitoGFP and UAS-lacZ were obtained from the
Bloomington Drosophila Stock Center. UAS-lacZ-RNAi (#51446), UAS-HDAC6-
RNAi (#108831) and UAS-Sirt2-RNAi (#21999) were obtained from the Vienna
Drosophila Resource Centre65. Flight and climbing assays were performed as
previously described66.
Dissection and imaging of axonal transport in Drosophila. Live dissections of
wandering third instar larvae were performed as previously described67. Individual
larvae were placed on Sylgard slide and pinned on both ends with the dorsal side
up. Larval body wall muscles were carefully opened using microdissection scissors.
Internal organs were removed with forceps without disturbing the ventral ganglion
and motor neurons. The cuticle was laterally expanded on both sides and pinned.
The whole preparation was washed in 1ml dissecting buffer containing 128mM
NaCl, 1mM EGTA, 4mM MgCl2, 2mM KCl, 5mM HEPES and 36mM sucrose,
pH 7.2. The buffer was replaced and the larvae kept immersed in buffer during
imaging. Imaging was done on an Olympus FV1000 confocal using  60 water
immersion objective (NA 0.90, Olympus LUMPLFL). Time-lapse movies were
acquired at the rate of 1 frame per 5 s for 500 s. A minimum of 10 movies
(one movie per larva) were taken for each genotype/treatment.
Analysis of mitochondrial movement in Drosophila. All movies were analysed
using ImageJ software. The movies were processed in ImageJ and kymographs
were generated as previously described59. Using kymographs, the number of
mitochondria moving in anterograde and retrograde directions were quantiﬁed
along with the number of stationary mitochondria. Mitochondria were scored as
moving if the organelle is in motion for at least 60% of the movie. All scoring was
performed blind to the experimental condition.
Drug treatment in Drosophila. Crosses were raised in standard medium sup-
plemented with 10mM TSA (Sigma-Aldrich T8552). Dimethylsulphoxide (0.06%)
was used as a control. For adult climbing, crosses with D42-GAL4 were raised in
standard medium and young progeny of 1–2 days were collected. Flies were starved
in empty vials for 3–4 h at 25 C and then placed in vials with ﬁlter papers soaked
with 1ml solution containing 10% sucrose and 100mM TSA68. Dimethylsulphoxide
Figure 6 | Axonal transport and locomotion is restored by TSA treatment. (a) Kymographs show transport of DsRed-labelled mitochondria in rat
cortical neurons transfected with acGFP1-tagged LRRK2 variants as indicated and treated with vehicle (Ctrl) or 0.5 mM TSA for 4 h. Charts are
mean±s.e.m. of quantiﬁed mitochondrial transport shown as percentage of total mitochondria. (b) Kymographs of mitochondria in transgenic Drosophila
motor neurons expressing mito-GFP and indicated LRRK2 variants. Ctrl is expressing a lacZ transgene. Drosophila were raised on food containing vehicle
control (Ctrl) or 10mM TSA. Charts are mean±s.e.m. of quantiﬁed mitochondrial transport shown as percentage of total mitochondria. (c) Locomotion
assays for climbing behavior following vehicle control or TSA treatment. Drosophila were raised on normal food, then fed vehicle (Ctrl) or TSA
supplemented food for 5 days before testing. Transgene expression is driven by D42-GAL4. *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, two-way
analysis of variance followed by Fisher’s least signiﬁcant difference post hoc test. (a) N (cells; from three to ﬁve experiments)¼WT Ctrl, 30; WT TSA, 7;
Y1699C Ctrl, 20; Y1699C TSA, 5; (b) N (animals)¼WT Ctrl, 10; WTþTSA, 10; R1441C Ctrl, 13; R1441CþTSA, 13; Y1699C Ctrl, 11; Y1699CþTSA, 11;
(c), right chart: N (animals)¼Ctrl Ctrl, 84; CtrlþTSA, 77; WT Ctrl, 68; WTþTSA, 46; R1441C Ctrl, 43; R1441CþTSA, 53; left chart: N (animals)¼Ctrl
Ctrl, 41; CtrlþTSA, 45; WT Ctrl, 56; WTþTSA, 78; Y1699C Ctrl, 59; Y1699CþTSA, 87.
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(0.6%) was used as a control. The ﬁlter papers were checked every day and replaced
after 48 h. Climbing assays were performed after 5 days, that is, animals were 6–7
days old.
Statistical analysis. Calculations and statistical analysis were performed using
Excel (Microsoft Corporation, Redmond, WA), and Prism software (GraphPad
Software, Inc., San Diego, CA). Statistical signiﬁcance was determined by one-way
or two-way analysis of variance (ANOVA) followed by Fisher’s least signiﬁcant
difference post hoc test or by t-test as indicated in the ﬁgure legends.
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